• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by IMV Inc.

    7/26/23 2:34:22 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care
    Get the next $IMV alert in real time by email
    6-K 1 imv6knr.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JULY, 2023 Filed by e3 Filing, Computershare 1-800-973-3274 - IMV Inc. - Form 6-K


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of July, 2023

    Commission File Number: 001-38480

    IMV Inc.
    (Name of registrant)

    130 Eileen Stubbs Avenue, Suite 19
    Dartmouth, Nova Scotia
    B3B 2C4, Canada

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    [ X ] Form 20-F [   ] Form 40-F

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [   ]

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [   ]






    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      IMV Inc.
     
    Date: July 26, 2023 By: /s/ Brittany Davison
      Name: Brittany Davison
      Title: Chief Accounting Officer

     





    Form 6-K Exhibit Index

    Exhibit
    Number
    Document Description
    99.1 IMV Inc. Announces Update on CCAA Proceedings and Sales and Investment Solicitation Process

     



    Get the next $IMV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMV

    DatePrice TargetRatingAnalyst
    9/22/2021$4.00Overweight
    Cantor Fitzgerald
    7/23/2021$14.00Overweight
    Wells Fargo
    More analyst ratings

    $IMV
    SEC Filings

    View All

    SEC Form 15-12G filed by IMV Inc.

    15-12G - IMV Inc. (0001734768) (Filer)

    9/22/23 4:22:10 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    SEC Form F-10POS filed by IMV Inc.

    F-10POS - IMV Inc. (0001734768) (Filer)

    9/22/23 4:19:43 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    SEC Form F-10POS filed by IMV Inc.

    F-10POS - IMV Inc. (0001734768) (Filer)

    9/22/23 4:19:22 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    $IMV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on IMV with a new price target

    Cantor Fitzgerald initiated coverage of IMV with a rating of Overweight and set a new price target of $4.00

    9/22/21 6:17:21 AM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    Wells Fargo resumed coverage on IMV with a new price target

    Wells Fargo resumed coverage of IMV with a rating of Overweight and set a new price target of $14.00

    7/23/21 7:10:01 AM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    $IMV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IMV Receives NASDAQ Delisting Notice

    IMV Inc. (the "Company" or "IMV") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that it was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that Nasdaq, in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, has in exercising its discretion determined to delist the Company's common shares as a result of the Company's announcement on May 1, 2023 that the Nova Scotia Supreme Court had issued an initial order (the "Initial Order") granting the Company and its subsidiaries prote

    5/8/23 4:30:00 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    Horizon Technology Finance Announces First Quarter 2023 Financial Results

    - First Quarter 2023 Net Investment Income per Share of $0.46; NAV per Share of $11.34 - - Debt Portfolio Yield of 16.3% - - Grew Portfolio Year over Year by 39% to $715 Million - - Horizon Platform Ends Quarter with Committed Backlog of $218 Million, Including $187 Million in HRZN Commitments - - Declares Regular Monthly Distributions Totaling $0.33 per Share - FARMINGTON, Conn., May 2, 2023 /PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ:HRZN) ("HRZN", "Horizon" or the "Company"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and

    5/2/23 4:15:00 PM ET
    $HRZN
    $IMV
    Finance: Consumer Services
    Finance
    Pharmaceuticals and Biotechnology
    Health Care

    IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic Alternatives

    IMV Inc. (the "Company" or "IMV") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical Company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced today that the Nova Scotia Supreme Court (the "Court") has issued an initial order (the "Initial Order") granting the Company and its subsidiaries protection under the Companies' Creditors Arrangement Act (R.S.C., 1985, c. C-36) (the "CCAA"). The Company will seek the recognition of the Initial Order in the United States by filing a petition commencing proceedings under the Chapter 15 of the United States Bankruptcy Code. After a careful review of available

    5/1/23 12:30:00 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    $IMV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by IMV Inc.

    SC 13G - IMV Inc. (0001734768) (Subject)

    2/14/23 12:57:14 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    SEC Form SC 13G/A filed by IMV Inc. (Amendment)

    SC 13G/A - IMV Inc. (0001734768) (Subject)

    2/3/23 12:06:43 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    SEC Form SC 13G/A filed by IMV Inc. (Amendment)

    SC 13G/A - IMV Inc. (0001734768) (Subject)

    7/21/21 2:03:29 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    $IMV
    Financials

    Live finance-specific insights

    View All

    Horizon Technology Finance Announces First Quarter 2023 Financial Results

    - First Quarter 2023 Net Investment Income per Share of $0.46; NAV per Share of $11.34 - - Debt Portfolio Yield of 16.3% - - Grew Portfolio Year over Year by 39% to $715 Million - - Horizon Platform Ends Quarter with Committed Backlog of $218 Million, Including $187 Million in HRZN Commitments - - Declares Regular Monthly Distributions Totaling $0.33 per Share - FARMINGTON, Conn., May 2, 2023 /PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ:HRZN) ("HRZN", "Horizon" or the "Company"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and

    5/2/23 4:15:00 PM ET
    $HRZN
    $IMV
    Finance: Consumer Services
    Finance
    Pharmaceuticals and Biotechnology
    Health Care

    IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023

    IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Thursday, March 16, 2023, at 8:00 a.m. ET to discuss the company's 2022 fourth quarter and fiscal year-end financial and operational results. Financial analysts are invited to join the conference call by registering at this link prior the call to receive their individual dial-in information. Other interested parties will be able to access the live audio webcast at this link: https://ir.imv-inc.com/events-and-presentations. The webcast will be

    3/9/23 7:05:00 AM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    IMV Inc. Announces Third Quarter 2022 Financial and Operational Results

    IMV Inc. (NASDAQ:IMV, TSX:IMV) ("IMV" or the "Company"), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced its financial and operational results and provided an update for the third quarter ended September 30, 2022. "IMV worked diligently to deliver on our clinical goals in the third quarter. We restructured the business to facilitate the achievement of these objectives and remain on track to present meaningful clinical data early next year," said Andrew Hall, Chief Executive Officer of IMV. "We expect 2023 to be a potentially transformative year for IMV, w

    11/10/22 4:05:00 PM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    $IMV
    Leadership Updates

    Live Leadership Updates

    View All

    IMV Inc. Announces Strategic Reorganization

    Reorganization enhances organizational focus on strategic priorities Clinical update on DLBCL patients in Phase 2B VITALIZE trial to be provided in September Appointment of Dr. Saman Maleki to Board of Directors Brittany Davison promoted to Chief Accounting Officer IMV Inc. (NASDAQ:IMV, TSX:IMV) ("IMV" or the "Company"), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat solid and hematologic cancers, today announced a strategic reorganization together with the appointment of Dr. Saman Maleki to the Company's Board of Directors and promotion of Brittany Davison to Chief Accounting Officer. "We have m

    9/15/22 7:45:00 AM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    IMV Announces Annual and Special Meeting of Shareholders Voting Results

    IMV Inc. ("IMV" or the "Company") (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced the voting results from its annual and special meeting of shareholders held on June 29, 2022 (the "Meeting"). Based on the votes received, all resolutions were accepted, including the election of directors, for whom details of the votes are as follows: Name of nominee Votes FOR % of votes FOR Votes Withheld % of votes Withheld Michael Bailey 27,525,895 99.11% 246,171 0.89% Brittany Davison 27,582,627 99.32% 189,439 0.68%

    6/30/22 7:05:00 AM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care

    IMV Appoints Andrew Hall as Chief Executive Officer

    IMV Inc. (NASDAQ:IMV, TSX:IMV), ("IMV" or "the Company"), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid tumors and blood cancers, announced today that its Board of Directors has appointed Andrew Hall to the role of Chief Executive Office and Director of the Board, effective January 1, 2022. "On behalf of the Board and the Company, I congratulate Andrew on his appointment to the Chief Executive Officer role. Over the last 5 months, Andrew has demonstrated strong leadership and refocused the Company to capitalize on its strengths in immuno-oncology, as well as a strategy designed to fully realize IMV's clear poten

    12/22/21 7:05:00 AM ET
    $IMV
    Pharmaceuticals and Biotechnology
    Health Care